Egle Zalyte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Egle Zalyte has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Aiste Avizaite
Faculty of Medicine, Vilnius University, LT‑03101 Vilnius, Lithuania
1 shared publicationAudrius Sileikis
Institute of Clinical Medicine, Clinic of Gastroenterology, Nephrology and Surgery, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
1 shared publicationBenediktas Kurlinkus
Institute of Clinical Medicine, Clinic of Gastroenterology, Nephrology and Surgery, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
1 shared publicationEgle Balciunaite
Laboratory of Molecular Oncology, National Cancer Institute, LT‑08406 Vilnius, Lithuania
1 shared publicationIeva Norkaityte
Department of Biochemistry and Molecular Biology, Institute of Biosciences, Life Sciences Center, Vilnius University, LT‑10257 Vilnius, Lithuania
1 shared publication- Jonas Cicenas
Faculty of Computing, Engineering and Technologies, Kauno kolegija Higher Education Institution, Kaunas, Lithuania, Lithuania
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 69 (5) , 1-20
Nucleocytoplasmic transport in gynaecological cancer: From mechanisms to therapeutic potential (Review)
Proper localization of proteins and RNAs in a cell is crucial for physiological function and cellular homeostasis, while disruption of the nucleocytoplasmic transport machinery leads to carcinogenesis. In gynaecological (endometrial, cervical and ovarian) tumours, upregulated nuclear transport protein expression promotes malignant cell proliferation, invasion and resistance to therapy. Therefore, therapeutic targeting of nuclear transport proteins has emerged as a promising anticancer approach. Researchers have extensively studied both nuclear import and export inhibitors in preclinical settings, alone or in combination with other targeted therapy agents. However, to date, only one compound, the exportin 1 inhibitor Selinexor, has been approved for cancer treatment. The development of nuclear transport inhibition‑based therapies is hindered by limited inhibitor specificity and complex cellular resistance mechanisms. The aim of the present review was to clarify the connection between nuclear transport dysregulation, hallmarks of gynaecological tumours and the challenges of inhibiting nuclear transport in gynaecological cancer treatment.
- 8 October 2026
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 69 (5) , 1-20
Open AccessNucleocytoplasmic transport in gynaecological cancer: From mechanisms to therapeutic potential (Review)
Proper localization of proteins and RNAs in a cell is crucial for physiological function and cellular homeostasis, while disruption of the nucleocytoplasmic transport machinery leads to carcinogenesis. In gynaecological (endometrial, cervical and ovarian) tumours, upregulated nuclear transport protein expression promotes malignant cell proliferation, invasion and resistance to therapy. Therefore, therapeutic targeting of nuclear transport proteins has emerged as a promising anticancer approach. Researchers have extensively studied both nuclear import and export inhibitors in preclinical settings, alone or in combination with other targeted therapy agents. However, to date, only one compound, the exportin 1 inhibitor Selinexor, has been approved for cancer treatment. The development of nuclear transport inhibition‑based therapies is hindered by limited inhibitor specificity and complex cellular resistance mechanisms. The aim of the present review was to clarify the connection between nuclear transport dysregulation, hallmarks of gynaecological tumours and the challenges of inhibiting nuclear transport in gynaecological cancer treatment.
- Open Access
- 20 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 75
Ferroptosis, Metabolic Rewiring, and Endometrial Cancer
Ferroptosis is a newly discovered form of regulated cell death. The main feature of ferroptosis is excessive membrane lipid peroxidation caused by iron-mediated chemical and enzymatic reactions. In normal cells, harmful lipid peroxides are neutralized by glutathione peroxidase 4 (GPX4). When GPX4 is inhibited, ferroptosis occurs. In mammalian cells, ferroptosis serves as a tumor suppression mechanism. Not surprisingly, in recent years, ferroptosis induction has gained attention as a potential anticancer strategy, alone or in combination with other conventional therapies. However, sensitivity to ferroptosis inducers depends on the metabolic state of the cell. Endometrial cancer (EC) is the sixth most common cancer in the world, with more than 66,000 new cases diagnosed every year. Out of all gynecological cancers, carcinogenesis of EC is mostly dependent on metabolic abnormalities. Changes in the uptake and catabolism of iron, lipids, glucose, and glutamine affect the redox capacity of EC cells and, consequently, their sensitivity to ferroptosis-inducing agents. In addition to this, in EC cells, ferroptosis-related genes are usually mutated and overexpressed, which makes ferroptosis a promising target for EC prediction, diagnosis, and therapy. However, for a successful application of ferroptosis, the connection between metabolic rewiring and ferroptosis in EC needs to be deciphered, which is the focus of this review.
- 20 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 75
Open AccessFerroptosis, Metabolic Rewiring, and Endometrial Cancer
Ferroptosis is a newly discovered form of regulated cell death. The main feature of ferroptosis is excessive membrane lipid peroxidation caused by iron-mediated chemical and enzymatic reactions. In normal cells, harmful lipid peroxides are neutralized by glutathione peroxidase 4 (GPX4). When GPX4 is inhibited, ferroptosis occurs. In mammalian cells, ferroptosis serves as a tumor suppression mechanism. Not surprisingly, in recent years, ferroptosis induction has gained attention as a potential anticancer strategy, alone or in combination with other conventional therapies. However, sensitivity to ferroptosis inducers depends on the metabolic state of the cell. Endometrial cancer (EC) is the sixth most common cancer in the world, with more than 66,000 new cases diagnosed every year. Out of all gynecological cancers, carcinogenesis of EC is mostly dependent on metabolic abnormalities. Changes in the uptake and catabolism of iron, lipids, glucose, and glutamine affect the redox capacity of EC cells and, consequently, their sensitivity to ferroptosis-inducing agents. In addition to this, in EC cells, ferroptosis-related genes are usually mutated and overexpressed, which makes ferroptosis a promising target for EC prediction, diagnosis, and therapy. However, for a successful application of ferroptosis, the connection between metabolic rewiring and ferroptosis in EC needs to be deciphered, which is the focus of this review.
- Open Access
- 4 May 2022
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 49 (6) , 1-14
Starvation mediates pancreatic cancer cell sensitivity to ferroptosis via ERK1/2, JNK and changes in the cell mesenchymal state
Pancreatic cancer is a highly metastatic and therapy‑resistant disease. In the present study, the prospects of a novel approach to kill pancreatic cancer cells were examined: Starvation combined with ferroptosis induction. Established pancreatic cancer cell lines (Miapaca2, Panc‑1, Su.86.86 and T3M4), as well as a unique cell line, Capan‑26, which was originally derived in the authors' laboratory, were used. Cells were deprived from growth factors, amino acids and pseudo‑starved using treatment with mTOR inhibitors; erastin was used to induce ferroptosis. Cell viability and lipid peroxidation measurements using flow cytometry revealed that the starved pancreatic cancer cells reacted differently to ferroptosis induction: The Panc‑1, Su.86.86 and T3M4 cells gained sensitivity, while the Miapaca2 cells acquired resistance. Fluorescence microscopy revealed that ERK1/2 translocated to the nucleus of the starved pancreatic cancer cells. Moreover, ERK1/2 pharmacological inhibition with SCH772984 prevented erastin‑induced ferroptosis in the starved Panc‑1, Su.86.86 and T3M4 cells. Confocal microscopy also indicated JNK activation. However, the inhibition of this kinase revealed its unexpected role in oxidative stress management: Treatment with the JNK inhibitor, SP600125, increased the viability of pseudo‑starved cells following erastin treatment. In addition, the FBS‑starved Miapaca2 and Capan‑26 cells transitioned between epithelial and mesenchymal cell states. The results were further confirmed using wound healing assays, western blot analysis and microscopic analysis of epithelial‑to‑mesenchymal transition (EMT) markers. Mesenchymal properties were associated with a higher sensitivity to erastin, whereas epithelial‑like cells were more resistant. Finally, it was demonstrated that compounds targeting EMT‑related signaling pathways increased cell sensitivity to erastin. On the whole, these results confirm that in starved pancreatic cancer cells, ERK1/2 and JNK signaling, as well as switching between epithelial and mesenchymal states mediates sensitivity to erastin and reveal novel therapeutic prospects of the combination of starvation with ferroptosis induction.
- 4 May 2022
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 49 (6) , 1-14
Open AccessStarvation mediates pancreatic cancer cell sensitivity to ferroptosis via ERK1/2, JNK and changes in the cell mesenchymal state
Pancreatic cancer is a highly metastatic and therapy‑resistant disease. In the present study, the prospects of a novel approach to kill pancreatic cancer cells were examined: Starvation combined with ferroptosis induction. Established pancreatic cancer cell lines (Miapaca2, Panc‑1, Su.86.86 and T3M4), as well as a unique cell line, Capan‑26, which was originally derived in the authors' laboratory, were used. Cells were deprived from growth factors, amino acids and pseudo‑starved using treatment with mTOR inhibitors; erastin was used to induce ferroptosis. Cell viability and lipid peroxidation measurements using flow cytometry revealed that the starved pancreatic cancer cells reacted differently to ferroptosis induction: The Panc‑1, Su.86.86 and T3M4 cells gained sensitivity, while the Miapaca2 cells acquired resistance. Fluorescence microscopy revealed that ERK1/2 translocated to the nucleus of the starved pancreatic cancer cells. Moreover, ERK1/2 pharmacological inhibition with SCH772984 prevented erastin‑induced ferroptosis in the starved Panc‑1, Su.86.86 and T3M4 cells. Confocal microscopy also indicated JNK activation. However, the inhibition of this kinase revealed its unexpected role in oxidative stress management: Treatment with the JNK inhibitor, SP600125, increased the viability of pseudo‑starved cells following erastin treatment. In addition, the FBS‑starved Miapaca2 and Capan‑26 cells transitioned between epithelial and mesenchymal cell states. The results were further confirmed using wound healing assays, western blot analysis and microscopic analysis of epithelial‑to‑mesenchymal transition (EMT) markers. Mesenchymal properties were associated with a higher sensitivity to erastin, whereas epithelial‑like cells were more resistant. Finally, it was demonstrated that compounds targeting EMT‑related signaling pathways increased cell sensitivity to erastin. On the whole, these results confirm that in starved pancreatic cancer cells, ERK1/2 and JNK signaling, as well as switching between epithelial and mesenchymal states mediates sensitivity to erastin and reveal novel therapeutic prospects of the combination of starvation with ferroptosis induction.
- 3 March 2021
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 41 (3) , 1401-1406
Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26
Background/Aim: Pancreatic ductal adenocarcinoma is one of the deadliest forms of human cancer. Since only a vast panel of cell lines can fully recapitulate disease heterogeneity, our aim was to establish a new pancreatic cancer cell line. Materials and Methods: Newly established pancreatic ductal adenocarcinoma cell line Capan-26 was characterized by assessing growth rate, tumor and stem cell marker expression, colony forming efficiency, mutations of KRAS and TP53 genes, karyotype and sensitivity to drug treatment. Results: Cell doubling time was 74 h. We detected CA19-9, CEACAM6, CD44, OCT4 and ZEB1 expression in Capan-26 cell line. Cells formed colonies in soft agar, have a deletion of KRAS exon 3 and a point mutation V172F in TP53 exon 5. They are a mixed aneuploid/polyploid population with high sensitivity to gemcitabine. Conclusion: Capan-26 is a unique cell line that may be used to study the mechanism of pancreatic cancer.
- 3 March 2021
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 41 (3) , 1401-1406
Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26
Background/Aim: Pancreatic ductal adenocarcinoma is one of the deadliest forms of human cancer. Since only a vast panel of cell lines can fully recapitulate disease heterogeneity, our aim was to establish a new pancreatic cancer cell line. Materials and Methods: Newly established pancreatic ductal adenocarcinoma cell line Capan-26 was characterized by assessing growth rate, tumor and stem cell marker expression, colony forming efficiency, mutations of KRAS and TP53 genes, karyotype and sensitivity to drug treatment. Results: Cell doubling time was 74 h. We detected CA19-9, CEACAM6, CD44, OCT4 and ZEB1 expression in Capan-26 cell line. Cells formed colonies in soft agar, have a deletion of KRAS exon 3 and a point mutation V172F in TP53 exon 5. They are a mixed aneuploid/polyploid population with high sensitivity to gemcitabine. Conclusion: Capan-26 is a unique cell line that may be used to study the mechanism of pancreatic cancer.